Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
KY/TN Water Profession...KY/TN Water Professionals
Not Confirmed
Not Confirmed
08-11 September, 2024
Pharmaconex 2024Pharmaconex 2024
Not Confirmed
Not Confirmed
08-10 September, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
KY/TN Water Profession...KY/TN Water Professionals
Industry Trade Show
Not Confirmed
08-11 September, 2024
Pharmaconex 2024Pharmaconex 2024
Industry Trade Show
Not Confirmed
08-10 September, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-re-unlocking-life-changing-potential-in-complex-molecules-without-sacrificing-time-to-market
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-hit-record-high-in-q1-2024-impacts-cancer-adhd-drugs-lilly-novo-ramp-up-production
Details:
As part of the agreement, ASOFARMA will collaborate with Moderna in the management of supply contracts already in force, as well as in vaccine registration processes, support for pharmacovigilance activities, and generation of new agreements for the availability of SPIKEVAX.
Lead Product(s): Elasomeran
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 23, 2022
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the agreement, ASOFARMA will collaborate with Moderna in the management of supply contracts already in force, as well as in vaccine registration processes, support for pharmacovigilance activities, a...
Product Name : Spikevax
Product Type : Vaccine
Upfront Cash : Undisclosed
February 23, 2022
Details:
Agreement with Adium Pharma will support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America. The agreement covers 18 countries in Latin America, including Brazil, Mexico, Colombia, and Argentina.
Lead Product(s): Elasomeran
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Adium Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 22, 2022
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Adium Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
Details : Agreement with Adium Pharma will support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America. The agreement covers 18 countries in Latin America, including Brazil, Mexico, Colom...
Product Name : Spikevax
Product Type : Vaccine
Upfront Cash : Undisclosed
February 22, 2022
Details:
Through agreement, Adium will be able to commercialize the marine-derived anticancer drug Yondelis (trabectedin), which is used in the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: PharmaMar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 27, 2020
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmamar Signs a New Agreement with Adium Pharma S.A. to Commercialize Yondelis® in Latin Americ...
Details : Through agreement, Adium will be able to commercialize the marine-derived anticancer drug Yondelis (trabectedin), which is used in the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Product Name : Yondelis
Product Type : Small molecule
Upfront Cash : Undisclosed
July 27, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?